Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $16

Benzinga · 04/17 17:39
Goldman Sachs analyst Andrea Tan maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $18 to $16.